Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials

Anti‐cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) and anti‐programmed cell death‐1 (PD‐1) inhibitors have been shown to significantly improve survival in patients with metastatic cutaneous melanoma. However, there was some heterogeneity as well as some variation in the degree of benefit acro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Seongseok, Vincelette, Nicole D., Green, Myke R., Wahner Hendrickson, Andrea E., Abraham, Ivo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867662/
https://www.ncbi.nlm.nih.gov/pubmed/27167347
http://dx.doi.org/10.1002/cam4.732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867662/
https://www.ncbi.nlm.nih.gov/pubmed/27167347
http://dx.doi.org/10.1002/cam4.732

Ejemplares similares